242 related articles for article (PubMed ID: 32412351)
1. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Hagihara K; Kashii M; Kitaguchi K; Matsuoka H; Iwahashi T; Chijimatsu R; Yoshikawa H
J Bone Miner Metab; 2018 Jul; 36(4):478-487. PubMed ID: 28766140
[TBL] [Abstract][Full Text] [Related]
3. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis.
Miyoshi A; Kameda H; Nagai S; Nakamura A; Miya A; Takase T; Atsumi T; Miyoshi H
J Diabetes Investig; 2021 Jul; 12(7):1293-1300. PubMed ID: 33141482
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
Oue T; Shimizu T; Asano T; Shimodan S; Ishizu H; Arita K; Iwasaki N
Calcif Tissue Int; 2023 Jun; 112(6):683-690. PubMed ID: 37037949
[TBL] [Abstract][Full Text] [Related]
6. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
7. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
[TBL] [Abstract][Full Text] [Related]
8. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
[TBL] [Abstract][Full Text] [Related]
9. The impact of switching once-weekly teriparatide to denosumab in osteoporosis patients.
Miyagi M; Fujimaki H; Naruse K; Suto K; Inoue G; Nakazawa T; Imura T; Saito W; Uchida K; Shirasawa E; Takahira N; Takaso M
J Orthop Sci; 2019 Jan; 24(1):153-158. PubMed ID: 30146385
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
Dito G; Lugaresi M; Degradi C; Guabello G; Longhi M; Corbetta S
Endocrine; 2023 Oct; 82(1):181-189. PubMed ID: 37402061
[TBL] [Abstract][Full Text] [Related]
11. Twenty-four months of follow-up in women with rebound-associated vertebral fractures after discontinuation of denosumab: a single-centre case series.
Clifton Goldney D; Pelegrin C; Jerkovich F; Longobardi V; Gonzalez Rodriguez E; Zanchetta MB
Osteoporos Int; 2024 Jan; 35(1):165-171. PubMed ID: 37702746
[TBL] [Abstract][Full Text] [Related]
12. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
[TBL] [Abstract][Full Text] [Related]
13. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
[TBL] [Abstract][Full Text] [Related]
14. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis.
Ebina K; Hashimoto J; Kashii M; Hirao M; Kaneshiro S; Noguchi T; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2017 Jan; 35(1):91-98. PubMed ID: 26762133
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.
Anastasilakis AD; Polyzos SA; Yavropoulou MP; Appelman-Dijkstra NM; Ntenti C; Mandanas S; Papatheodorou A; Makras P
Calcif Tissue Int; 2021 May; 108(5):587-594. PubMed ID: 33386953
[TBL] [Abstract][Full Text] [Related]
16. Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis.
Hong N; Shin S; Lee S; Kim KJ; Rhee Y
Calcif Tissue Int; 2022 Jul; 111(1):47-55. PubMed ID: 35226133
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.
Lyu H; Zhao SS; Yoshida K; Tedeschi SK; Xu C; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 Nov; 104(11):5611-5620. PubMed ID: 31265071
[TBL] [Abstract][Full Text] [Related]
18. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
[TBL] [Abstract][Full Text] [Related]
19. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
[TBL] [Abstract][Full Text] [Related]
20. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]